Cargando…
Improving the operational efficiency of Phase 2 and 3 trials
The period toward the end of patients’ participation in late stage blinded clinical trials is highly resource intensive for the sponsor. Consider first a Phase 3 trial. If the trial is a success, the sponsor has to implement the next steps, which might be filing for approval of the drug with the US...
Autor principal: | Ganju, Jitendra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955134/ https://www.ncbi.nlm.nih.gov/pubmed/27439520 http://dx.doi.org/10.1186/s13063-016-1465-3 |
Ejemplares similares
-
Non-inferiority versus superiority drug claims: the (not so) subtle distinction
por: Ganju, Jitendra, et al.
Publicado: (2017) -
Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer
por: Snowdon, Claire, et al.
Publicado: (2022) -
Improving clinical trial efficiency: Is technology the answer?
por: French, Jacqueline A.
Publicado: (2017) -
Adaptive trials, efficiency, and ethics
por: Hey, Spencer Phillips
Publicado: (2019) -
Clinical development and trial operations in COVID-19 era
por: Choe, Seong Choon
Publicado: (2021)